Dr. Scott M. Glaser, MD

Dr. Glaser practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Glaser's NPI, 1750643136, was assigned on June 12, 2012. Dr. Glaser graduated from Loyola University Chicago Stritch School of Medicine in 2012. Dr. Glaser holds California license A147996.

Dr. Glaser's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Glaser's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Glaser to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Glaser practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Glaser's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Glaser is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Glaser's licenses on file in 3 states: California, Pennsylvania and Nevada.

Dmand AI lists bone cancer radiation, brain cancer radiation, breast cancer radiation, cervical cancer radiation, head & neck cancer radiation, lung cancer radiation, lymphoma radiation and prostate cancer radiation among the conditions Dr. Glaser treats.

CMS data shows 2,234 Medicare services from Dr. Glaser across 20 procedure codes in 2024, for 295 Medicare patients. Medicare paid $195,556 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 295 Medicare patients who saw Dr. Glaser in 2024. The largest group is 65 to 74, with 150 patients. 75% of them have cancer, and 75% have high blood pressure. 27% are also on Medicaid. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Glaser's median patient age at 69, with 60% women.

In 2024, Dr. Glaser wrote 169 Medicare Part D claims for 69 patients. 100% of them were for generic drugs. CMS names the drug for 156 of them, across 4 drugs with 11 or more claims each, at $329 in total drug cost. In 2023, CMS named 240 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Glaser for performance year 2024, reported as part of a group. Dr. Glaser accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Glaser as offering telehealth.

Dmand AI links 112 papers to Dr. Glaser, published from 2005 to 2025. 2019 was the busiest year, with 13. The most frequent topics are Brachytherapy, Uterine Cervical Neoplasms and Radiotherapy Dosage. Dr. Glaser has published most often in Brachytherapy. Dr. Glaser's most frequent co-authors are Sushil Beriwal, MD, Arya Amini, MD and Yi-Jen Chen, MD.

Dmand AI links Dr. Glaser to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Carcinoma, Intraductal, Noninfiltrating and Breast Carcinoma In Situ.

CMS Open Payments shows 7 general payments to Dr. Glaser from 4 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 82% of the total. C. R. Bard, Inc. & Subsidiaries paid the most, $1,149.

Dmand AI lists 4 awards for Dr. Glaser, most recently American Brachytherapy Society Research Travel Grant in 2016.

Dr. Glaser graduated from Loyola University Chicago Stritch School of Medicine in 2012. Dr. Glaser is a member of American Brachytherapy Society (ABS), American College of Radiation Oncology (ACRO), ASTRO and European Society of Therapeutic Radiation and Oncology (ESTRO).

Dr. Glaser is in network with 12 carriers, including Aetna, United Healthcare and Elevance. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.